Chondrosarcoma: the impact of comorbidity – 30 years of experience from a population-based database including 199 consecutive chondrosarcoma patients
Received 19 February 2019
Accepted for publication 23 July 2019
Published 3 September 2019 Volume 2019:11 Pages 109—116
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Nicola Ludin
Peer reviewer comments 2
Editor who approved publication: Professor Clark Hung
Ninna Aggerholm-Pedersen1,2, Katja Maretty-Nielsen3, Steen Baerentzen3, Peter Holmberg Jørgensen4, Bjarne Hauge Hansen4, Thomas Baad-Hansen4, Johnny Keller4, Akmal Safwat1
1Department of Oncology, Sarcoma Centre of Aarhus University Hospital, Aarhus, Denmark; 2Department of Experimental Clinical Oncology, Sarcoma Centre of Aarhus University Hospital, Aarhus, Denmark; 3Department of Orthopaedic Surgery, Sarcoma Centre of Aarhus University Hospital, Aarhus, Denmark; 4Department of Pathology, Sarcoma Centre of Aarhus University Hospital, Aarhus, Denmark
Correspondence: Ninna Aggerholm-Pedersen
Department of Oncology, Sarcoma Centre of Aarhus University Hospital, Palle Juul-Jensensens Boulevard 99, Aarhus N 8200, Denmark
Background: Adjustment for comorbidity when investigating potential prognostic factors, especially in elderly cancer patients, is imperative. Patients diagnosed with chondrosarcoma are elderly and more comorbidity is expected for these patients. Demographic changes are awaited in the future resulting in more and more elderly patients with comorbidity. The aims of this study were to characterize patients with chondrosarcoma treated at a single institute and to evaluate various prognostic factors for survival adjusted for comorbidity.
Material and methods: Between 1979 and 2008, 199 patients were treated at the Sarcoma Centre of Aarhus University Hospital, for chondrosarcoma. The incidence was calculated as a WHO age-standardized incidence rate (IR) per million per year. The endpoints were overall mortality and disease-specific mortality. Possible prognostic factors were analyzed for patients with intermediate/high-grade localized tumors by the uni- and multivariate Cox-proportional hazard method.
Results: The WHO age-standardized IR in western Denmark in the period 1979–2008 was 2.4/million inhabitants/year (95% CI: 2.2;2.6). The 5-year overall and disease-specific mortality for the 199 patients were 29% (95% CI: 23;36) and 22% (95% CI: 16;27), respectively. The 5-year disease-specific mortality for patients with metastatic disease was significantly higher than for patients with localized disease. The median time to relapse was 2.0 years. Patients who relapse within 1 year after the primary diagnosis have a significantly higher 5-year overall mortality compared to patients who relapse after 1 year. The presence of comorbidity and high-grade tumors were independent prognostic factors for both the overall mortality and the disease-specific mortality of chondrosarcoma patients.
Conclusion: Patients with comorbidity had a significantly increased overall mortality and disease-specific mortality. We found that adjusting for comorbidity is important when investigating a cohort of elderly patients.
Keywords: chondrosarcoma, comorbidity, prognostic factors
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]